Last reviewed · How we verify
Standard cyclophosphamide
Cyclophosphamide works by interfering with the growth of cancer cells, which are eventually destroyed.
Cyclophosphamide works by interfering with the growth of cancer cells, which are eventually destroyed. Used for Malignant lymphoma, Multiple myeloma, Leukemia.
At a glance
| Generic name | Standard cyclophosphamide |
|---|---|
| Sponsor | King Faisal Specialist Hospital & Research Center |
| Drug class | Alkylating agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cyclophosphamide is an alkylating agent that attaches an alkyl group to the DNA of cancer cells, interfering with their replication and causing cell death. This leads to the destruction of rapidly dividing cells, such as cancer cells.
Approved indications
- Malignant lymphoma
- Multiple myeloma
- Leukemia
- Solid tumors
Common side effects
- Myelosuppression
- Nausea and vomiting
- Hair loss
- Infection
- Bleeding
- Alopecia
- Diarrhea
- Stomatitis
- Fatigue
- Anemia
Key clinical trials
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (PHASE3)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists (PHASE1, PHASE2)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia (PHASE3)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |